L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 557.2 ILS 1.62% Market Closed
Market Cap: 440.6m ILS

Wall Street
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 297.48 ILS with a low forecast of 616.68 ILS and a high forecast of 2 884.97 ILS.

Lowest
Price Target
616.68 ILS
11% Upside
Average
Price Target
1 297.48 ILS
133% Upside
Highest
Price Target
2 884.97 ILS
418% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
NGNE
Neurogene Inc
188% Upside
ABBV
Abbvie Inc
11% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
32% Upside
ADMA
ADMA Biologics Inc
41% Upside
REGN
Regeneron Pharmaceuticals Inc
7% Upside
ARMP
Armata Pharmaceuticals Inc
56% Upside
301207
Hualan Biological Bacterin Inc
3% Downside
CGON
CG Oncology Inc
79% Upside

Revenue
Forecast

Revenue Estimate
Lineage Cell Therapeutics Inc

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 3 years is 35%.

6%
Past Growth
35%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LCTX's stock price target?
Price Target
1 297.48 ILS

According to Wall Street analysts, the average 1-year price target for LCTX is 1 297.48 ILS with a low forecast of 616.68 ILS and a high forecast of 2 884.97 ILS.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
35%

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 3 years is 35%.

Back to Top